Skip NavigationSkip to Content

Anticancer drug discovery and development throughout the world

  1. Author:
    Schwartsmann, G.
    Ratain, M. J.
    Cragg, G. M.
    Wong, J. E.
    Saijo, N.
    Parkinson, D. R.
    Fujiwara, Y.
    Pazdur, R.
    Newman, D. J.
    Dagher, R.
    Di Leone, L.
  2. Author Address

    Lutheran Univ Brazil, Ctr Comprehens Canc, S Amer Off Anticanc Drug Dev, Campus Cent ULBRA,Predio 22-5 Andar, Canoas, Brazil Lutheran Univ Brazil, Ctr Comprehens Canc, S Amer Off Anticanc Drug Dev, Canoas, Brazil Univ Fed Rio Grande Sul, Postgrad Course Med, Porto Alegre, RS, Brazil Univ Chicago, Dept Med, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA NCI, Nat Prod Branch, Dev Therapeut Program, Div Canc Treatment & Diag, Frederick, MD 21701 USA Natl Univ Singapore, Dept Hematol Oncol, Singapore 0511, Singapore Natl Canc Ctr, Div Med Oncol, Tokyo, Japan Minist Hlth Labor & Welf, Natl Inst Hlth Sci, Pharmaceut & Med Devices Evaluat Ctr, Tokyo, Japan Novartis Oncol, Translat Dev, Clin Res, E Hanover, NJ USA US FDA, Div Oncol Drug Prod, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA Schwartsmann G Lutheran Univ Brazil, Ctr Comprehens Canc, S Amer Off Anticanc Drug Dev, Campus Cent ULBRA,Predio 22-5 Andar, Canoas, Brazil
    1. Year: 2002
  1. Journal: Journal of Clinical Oncology
    1. 20
    2. 18, Suppl. S
    3. Pages: 47S-59S
  2. Type of Article: Article
  1. Abstract:

    This year's American Society of Clinical Oncology International Symposium devoted 2 hours to a lively discussion of various aspects of anticancer drug discovery and development throughout the world. The scientific program started with an overview of efforts directed toward promoting international collaboration in natural product-derived anticancer drug discovery. This was followed by a discussion on the importance of interethnic differences and pharmacogenetics in anticancer drug development. Thereafter, this part of the program was completed by a description of the activities of the newly created Singapore-Hong Kong-Australia Drug Development Consortium and an overview of the contribution of Japan to anticancer drug development. The logistics and regulatory aspects of clinical trials with new anticancer agents in different parts of the world were then presented, with an emphasis on Europe, North America, and Japan. The program was completed with a panel discussion of the efforts to harmonize the exchange of clinical data originating from one region of the globe with other territories, with input from official representatives of the United States Food and Drug Administration and the Medical Devices Evaluation Center of Japan.

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel